Morten Orebo Holmström

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite et al. · Nature Medicine · 2021 · 197 citations · Full text

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

Morten Orebo Holmström, Evelina Martinenaite, Shamaila Munir Ahmad et al. · Leukemia · 2017 · 87 citations

Medicine, Immunology, Immune Checkpoint Inhibitor +8

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Julia Czech, Sabrina Cordua, Barbora Weinbergerová et al. · Leukemia · 2018 · 57 citations

Transcriptional Regulation, Increased Molecular Responses, Signal Transduction +13

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

Jacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Dahlager Jørgensen et al. · Frontiers in Oncology · 2021 · 50 citations · Full text

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response

Morten Orebo Holmström, Caroline Hasselbalch Riley, Vibe Skov et al. · OncoImmunology · 2018 · 48 citations · Full text